VOLUME 47 | NUMBER 1.1 | FEBRUARY 2012
Pharmaceutical Price Controls and Minimum Efficacy Regulation: Evidence from the United States and Italy
Keywords: Pharmaceutical market; regulation; innovation.
Objective: This article examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of MES and price control mechanisms (MES + PC).
Data Sources: Our primary data source is the Tufts-New England Medical Center-Cost Effectiveness Analysis Registry which have been merged with price data taken from MEPS (for the United States) and AIFA (for Italy).
Study Design: Through a simple model of adverse selection we model the interaction between firms, heterogeneous buyers, and the regulator.
Principal Findings: The theoretical analysis provides two results. First, an MES regime provides greater incentives to produce high-quality drugs. Second, an MES + PC mix reduces the difference in price between the highest and lowest quality drugs on the market.
Conclusion: The empirical analysis based on United States and Italian data corroborates these results.
Copyright© 2017, Health Research & Educational Trust. All rights reserved. Content Disclaimer
Health Research & Educational Trust, 155 North Wacker, 4th Floor Chicago, IL 60606 (312) 422.2600